J. Michael Pearson

Chairman & Chief Executive Officer
Valeant Pharmaceuticals International

J. Michael Pearson is chairman and chief executive officer of Valeant Pharmaceuticals, an international pharmaceutical company specializing in the areas of dermatology, eye health, neurology and consumer healthcare. Valeant has 17,000 employees worldwide and revenues exceeding $8 billion.

Pearson has served on the board since September 2010 and as the chairman of the board since March 2011. From February 2008 to September 2010, he was the chairman of the board and chief executive officer of Valeant Pharmaceuticals International before the merger with Biovail. Under Pearson’s leadership, Valeant has grown from less than $800 million in revenue to over $8 billion and the company has completed over 50 acquisitions, including Salix Pharmaceuticals, Solta Medical and Bausch + Lomb.

Previously, Pearson was a consultant at McKinsey.